ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AKTX Akari Therapeutics PLC

1.52
0.00 (0.00%)
21 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Akari Therapeutics PLC NASDAQ:AKTX NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 1.52 1.15 1.75 1.60 1.495 1.56 22,630 00:53:23

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

11/12/2020 9:20pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

December 2020

 

Commission file number: 001-36288

 

Akari Therapeutics, Plc

(Translation of registrant's name into English)

 

75/76 Wimpole Street

London W1G 9RT

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x            Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ______________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ______________

 

 

 

 

CONTENTS

 

 

On December 11, 2020, Akari Therapeutics, Plc (the “Company”) issued a press release announcing new clinical data that show long-term self-administered nomacopan is well-tolerated and substantially reduces transfusion dependence in patients with paroxysmal nocturnal hemoglobinuria (PNH).

 

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information in paragraphs one, three, four, five, six, seven and nine of Exhibit 99.1 is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.

 

Exhibit No.

 

  99.1 Press release dated December 11, 2020

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Akari Therapeutics, Plc
  (Registrant)
     
       
  By: /s/ Clive Richardson
  Name:

Clive Richardson

Chief Executive Officer and Chief Operating Officer

  

 

Date: December 11, 2020

 

 

 

 

1 Year Akari Therapeutics Chart

1 Year Akari Therapeutics Chart

1 Month Akari Therapeutics Chart

1 Month Akari Therapeutics Chart

Your Recent History

Delayed Upgrade Clock